AbCellera Biologics vs Assembly Biosciences
ABCL and ASMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABCL and ASMB compare
AbCellera Biologics is the larger company, worth 8.2 times as much as Assembly Biosciences ($3.5B against $430M).
AbCellera Biologics grew revenue faster over the last twelve months (92.1% versus 80.2% for Assembly Biosciences).
Assembly Biosciences keeps more of each dollar of sales as profit, with a net margin of −16.6% compared with −219% at AbCellera Biologics.
Assembly Biosciences scores higher on the StockData Score (12 against 8 for AbCellera Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABCL | ASMB |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | $430M |
| Share price | $11.49 | $21.12 |
| Change, 1 year | 189% | −41.1% |
| Change, 5 years | −27.3% | −23.5% |
| Beta (5Y) | 1.46 | 1.17 |
| Employees | 562 | 73 |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 51.9× | 6.4× (better) |
| P/B | 3.3× | 1.4× (better) |
| FCF yield | −0.93% (better) | −9.5% |
| Fair value | $4.50 | $22.88 |
| Margin of safety | −155% | 7.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 92.1% (better) | 80.2% |
| Revenue growth, 5Y average | −20.3% | −1.8% (better) |
| Profitability | ||
| Operating margin | −298% | −31.8% (better) |
| Net margin | −219% | −16.6% (better) |
| FCF margin | −48.4% (better) | −60.7% |
| Return on equity | −14.6% | −4.6% (better) |
| Return on invested capital | −41.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.43 | 12.89 (better) |
| Altman Z-score | 4.92 | 7.10 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 37.9% | 92.1% |
| Held by insiders | 22.8% | 29.3% |
| Insider net buying, 12 months | $3.2M (better) | −$252K |
| Short interest, % of float | 12.3% | 21.1% |
Go deeper
- ABCL stock overview
- ABCL income statement
- ABCL valuation and score
- ASMB stock overview
- ASMB income statement
- ASMB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.